Photosensitive Lithium Crown Ether Prodrug for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma lack effective neuroprotection for retinal ganglion cells, leading to progressive vision loss, and existing lithium therapies are hindered by severe side effects due to slow penetration and delayed onset of action.
Innovation Solution
A photosensitive prodrug system that releases lithium upon exposure to light, using a photosensitive moiety attached to a chelating moiety like crown ethers or aza-crown ethers, allowing controlled delivery of lithium specifically to the eye, minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional lithium therapy is used to protect retinal ganglion cells, then neuroprotection effect is achieved, but severe side effects occur due to slow penetration and delayed onset of action
Solution Approach 1:
The patent applies preliminary action by developing a photosensitive prodrug system that is prepared in advance but remains inactive until light exposure. The lithium compound is conjugated with a photosensitive moiety (azobenzene or spiropyran) that prevents premature activation, allowing the drug to be administered systemically without immediate therapeutic effect or side effects. Upon light exposure at the target site, the photosensitive group undergoes photoisomerization to release active lithium, achieving localized neuroprotection with minimized systemic toxicity.
Solution Approach 2:
The patent uses a photosensitive moiety (azobenzene or spiropyran) as an intermediary between the lithium compound and the biological system. This intermediary group acts as a protective mask that prevents the lithium from exerting its pharmacological effect until light activation occurs. The photosensitive moiety mediates the controlled release of lithium by undergoing photoisomerization, which triggers conformational changes that release the active lithium ion at the target site while keeping it inactive during circulation.
2Reliability
If lithium dosage is increased to overcome slow penetration, then therapeutic effect improves, but side effects worsen
Solution Approach 1:
The patent applies local quality by enabling spatially selective activation of the lithium prodrug through light exposure. The photosensitive prodrug system allows the lithium to be activated only at the target site (eye) where light can penetrate, while remaining inactive in other tissues. This creates a local concentration of active lithium at the retinal ganglion cells without requiring high systemic dosages, thereby achieving therapeutic effect with minimized side effects.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the photoisomerization property of the photosensitive moiety. Upon light exposure, the photosensitive group undergoes a change in molecular configuration (from trans to cis isomerization in azobenzene, or ring-opening in spiropyran), which triggers a conformational change in the entire prodrug molecule. This parameter change leads to the release of active lithium from the conjugated complex, enabling controlled activation without increasing the overall dosage.
3Object-affected harmful factors
If photosensitive prodrug system is used for targeted delivery, then side effects are minimized, but device complexity increases
Solution Approach 1:
The patent applies composite materials by creating a hybrid molecular structure that combines the lithium compound with a photosensitive moiety (azobenzene or spiropyran) and a chelating agent. This composite prodrug system integrates multiple functional components into a single molecule: the lithium ion for neuroprotection, the photosensitive group for light-responsive activation, and the chelating agent for stable complexation. The resulting composite structure enables targeted delivery and controlled release while maintaining a manageable molecular architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides targeted neuroprotection for retinal ganglion cells, reducing cell loss and vision impairment in glaucoma models, with a lower effective dosage and minimized side effects compared to traditional lithium treatments.
Implementation Method 1
The photosensitive moiety undergoes photoisomerization and causes an overall conformational change in the chelating moiety, thereby affecting its binding property
Implementation Method 2
a chelating moiety for lithium, wherein the photosensitive moiety undergoes photoisomerization and causes an overall conformational change in the chelating moiety
Data Source
AI summary
This invention provides a method for treating an eye disease in a patient comprising: providing a photosensitive prodrug that releases upon exposure to light an active ingredient to treat the eye disease; administering the prodrug in a pharmaceutically accepted vehicle to the subject, and exposing the eye of the subject to an external light source to cause the prodrug to release the active ingredient. This invention also provides a composition for the treatment of glaucoma, comprising a compound containing a lithium ion-chelated in a crown ether- or aza-crown ether-containing chromene or diazene derivative and a pharmaceutically acceptable carrier.